AMINOSYN 8.5% (PH6) Drug Patent Profile

When do Aminosyn 8.5% (ph6) patents expire, and when can generic versions of Aminosyn 8.5% (ph6) launch?

Aminosyn 8.5% (ph6) is a drug marketed by Icu Medical Inc and is included in one NDA.

The generic ingredient in AMINOSYN 8.5% (PH6) is amino acids. There are three hundred and fifty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the amino acids profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aminosyn 8.5% (ph6)

A generic version of AMINOSYN 8.5% (PH6) was approved as amino acids by B BRAUN on April 13^th, 2012.

Summary for AMINOSYN 8.5% (PH6)

US Patents:	0
Applicants:	1
NDAs:	1
DailyMed Link:	AMINOSYN 8.5% (PH6) at DailyMed

US Patents and Regulatory Information for AMINOSYN 8.5% (PH6)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Icu Medical Inc	AMINOSYN 8.5% (PH6)	amino acids	INJECTABLE;INJECTION	017673-007	Nov 18, 1985		DISCN	No	No

AMINOSYN 8.5% (PH6): Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

AMINOSYN 8.5% (PH6), a parenteral amino acid solution, demonstrates a stable market presence driven by its critical role in nutritional support for patients unable to consume food orally. Its financial trajectory is directly correlated with healthcare expenditure, hospital utilization rates, and the prevalence of conditions requiring intravenous feeding. Key market drivers include an aging global population, increasing incidence of gastrointestinal disorders, and advancements in critical care medicine.

What is the current market size and projected growth for AMINOSYN 8.5%?

The global market for parenteral nutrition, which includes amino acid solutions like AMINOSYN 8.5% (PH6), is substantial. In 2022, the parenteral nutrition market was valued at approximately $8.7 billion and is projected to reach $12.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.6% [1]. AMINOSYN 8.5% (PH6) captures a segment of this market. The growth is primarily fueled by the increasing demand for home parenteral nutrition and the rising prevalence of chronic diseases such as cancer, inflammatory bowel disease, and chronic kidney disease [2].

Key factors influencing market size and growth:

• Aging Population: Older adults are more susceptible to malnutrition and require nutritional support. The UN projects the global population aged 65 and over will reach 1.6 billion by 2050 [3].
• Prevalence of Chronic Diseases: Conditions necessitating parenteral nutrition are on the rise. For instance, the global incidence of inflammatory bowel disease (IBD) is estimated to be 3-50 per 100,000 population annually in Western countries [4].
• Advancements in Medical Technology: Improved delivery systems and formulations enhance the safety and efficacy of parenteral nutrition, expanding its use in various clinical settings.
• Hospitalization Rates: Increased hospital admissions, particularly in intensive care units (ICUs), directly correlate with the demand for intravenous nutritional products.

Who are the primary manufacturers and competitors in the AMINOSYN 8.5% market?

The market for amino acid solutions is characterized by a mix of large pharmaceutical corporations and specialized medical nutrition companies. While specific market share data for AMINOSYN 8.5% (PH6) is proprietary, its competitive landscape includes several major players. Baxter International Inc. is a significant manufacturer of parenteral nutrition products, including amino acid solutions. Other key competitors in the broader parenteral nutrition market include Fresenius Kabi AG, B. Braun Melsungen AG, and Pfizer Inc. [5].

Major manufacturers and their product portfolios within the parenteral nutrition segment:

• Baxter International Inc.: Offers a range of amino acid solutions and multi-chamber bags for parenteral nutrition.
• Fresenius Kabi AG: A prominent provider of IV drugs, infusion therapies, and clinical nutrition products.
• B. Braun Melsungen AG: Develops and manufactures a comprehensive portfolio of medical devices and pharmaceuticals, including parenteral nutrition.
• Nestlé Health Science: A key player in the medical nutrition sector, though its focus may be broader than solely intravenous amino acids.

Competition is based on product quality, price, availability, regulatory compliance, and distribution networks. The development of specialized amino acid formulations tailored to specific patient populations (e.g., neonates, burn victims, or those with liver or kidney disease) also represents a competitive differentiator.

What is the intellectual property landscape surrounding AMINOSYN 8.5%?

The intellectual property (IP) landscape for established amino acid solutions like AMINOSYN 8.5% (PH6) is primarily characterized by patent expirations for the original formulations and manufacturing processes. AMINOSYN 8.5% is a generic name for a standard amino acid solution. The core composition patents for such solutions have long since expired.

Key IP considerations:

• Composition of Matter Patents: Original patents covering the specific ratios and types of amino acids in formulations like AMINOSYN 8.5% are expired. This allows for generic production.
• Manufacturing Process Patents: While core manufacturing methods may be patented, continuous innovation in manufacturing technology can lead to new process patents that offer efficiencies or improved product purity. These can provide a competitive edge to manufacturers.
• Formulation Patents: Manufacturers may develop new formulations that enhance stability, solubility, or compatibility with other intravenous components. These can be protected by patents, extending market exclusivity for specific product variations.
• Delivery System Patents: Patents related to specialized infusion devices, bags, or administration sets designed for parenteral nutrition can also influence the market.
• Regulatory Exclusivity: While not IP in the traditional sense, regulatory pathways and data exclusivity periods granted by agencies like the U.S. Food and Drug Administration (FDA) can provide market protection for novel formulations or manufacturing changes.

Companies may also employ trade secrets for proprietary manufacturing techniques or quality control measures that are not publicly disclosed. The absence of strong, unexpired composition of matter patents on standard amino acid solutions means market entry for new manufacturers is primarily dependent on manufacturing capability and regulatory approval.

What are the key regulatory hurdles and compliance requirements for AMINOSYN 8.5%?

AMINOSYN 8.5% (PH6) is regulated as a parenteral drug, subject to stringent oversight by health authorities worldwide. Compliance with Good Manufacturing Practices (GMP) is paramount.

Key regulatory bodies and requirements:

• U.S. Food and Drug Administration (FDA): Products must comply with the Federal Food, Drug, and Cosmetic Act. This includes adherence to New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) requirements for approved versions, or being listed as an approved drug product. Manufacturing facilities are subject to FDA inspections. The FDA's Center for Drug Evaluation and Research (CDER) oversees these products.
• European Medicines Agency (EMA): Similar requirements apply in the European Union, with national competent authorities enforcing directives. Marketing Authorization Applications (MAAs) are required.
• Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP standards to ensure product quality, safety, and efficacy. This covers all aspects of production, from raw material sourcing to finished product testing and distribution.
• Pharmacopoeial Standards: Products must meet the standards set forth in official pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.), which define the identity, strength, quality, and purity of drug substances and products. For AMINOSYN 8.5%, this would include specifications for amino acid content, pH, sterility, and absence of pyrogens.
• Labeling and Packaging: Regulations dictate precise labeling requirements, including ingredient lists, indications, contraindications, dosage information, storage conditions, and warnings. Packaging must maintain product sterility and integrity.
• Post-Market Surveillance: Companies are required to monitor and report adverse events and product quality issues that arise after the product is on the market.

The complexity and cost of navigating these regulatory frameworks create significant barriers to entry for new manufacturers.

What is the typical pricing strategy and reimbursement landscape for AMINOSYN 8.5%?

The pricing strategy for AMINOSYN 8.5% (PH6) is influenced by several factors, including manufacturing costs, competitive pricing, regulatory compliance expenses, and perceived value in clinical settings. As a critical care product, its price reflects the specialized manufacturing processes and quality controls required.

Pricing and reimbursement factors:

• Cost-Plus Pricing: Manufacturers may use a cost-plus model, where pricing is determined by adding a markup to the cost of production, including raw materials, labor, quality control, and regulatory expenses.
• Competitive Benchmarking: Prices are benchmarked against similar amino acid solutions from competitors to remain competitive in the market.
• Wholesale Acquisition Cost (WAC): This is the manufacturer's list price for the drug. Actual selling prices may be lower due to discounts and rebates.
• Reimbursement: In hospital settings, the cost of AMINOSYN 8.5% is typically bundled into overall patient care costs and reimbursed through Diagnosis-Related Groups (DRGs) in the U.S. or similar global payment systems. This means reimbursement is tied to the patient's diagnosis and treatment, not the specific drug product in isolation.
• Payer Negotiations: For outpatient or home parenteral nutrition, payers (insurance companies, government health programs) may negotiate pricing with manufacturers or distributors.
• Value-Based Pricing: While less common for standard generics, there is a growing trend towards value-based pricing in healthcare, where drug prices are linked to their demonstrated clinical outcomes and cost-effectiveness.

The reimbursement landscape for parenteral nutrition is complex, with variations across different healthcare systems and insurance plans. Hospitals manage these costs through their established reimbursement structures.

What are the principal risks and opportunities for AMINOSYN 8.5%?

Risks:

• Generic Competition: The absence of strong patent protection for standard amino acid solutions intensifies competition from generic manufacturers, potentially leading to price erosion.
• Regulatory Changes: Evolving regulatory requirements for drug manufacturing, quality control, or pharmacopoeial standards can necessitate costly upgrades or product reformulations.
• Supply Chain Disruptions: Reliance on global supply chains for raw materials (amino acids, excipients) can lead to shortages or price volatility due to geopolitical events, natural disasters, or manufacturing issues at supplier sites.
• Adverse Event Reports: Any significant adverse events linked to AMINOSYN 8.5% could trigger regulatory scrutiny, product recalls, and damage to brand reputation, impacting sales.
• Technological Obsolescence: While AMINOSYN 8.5% is a well-established product, the development of novel nutritional therapies or advanced delivery systems could theoretically reduce its demand if they offer superior outcomes or convenience.
• Cost Containment Pressures: Healthcare systems globally face pressure to control costs, which can lead to greater scrutiny of drug pricing and reimbursement for essential but non-innovative therapies.

Opportunities:

• Growing Demand for Parenteral Nutrition: The underlying drivers for parenteral nutrition—aging populations, increased chronic disease, and advancements in critical care—are expected to continue, ensuring a baseline demand for essential amino acid solutions.
• Emerging Markets: Expansion into developing economies with improving healthcare infrastructure presents opportunities for increased sales, provided regulatory pathways are navigable and affordability is addressed.
• Formulation Enhancements: While core patents may be expired, opportunities exist for developing improved formulations. This could include enhanced stability, reduced osmolality, or combinations with other micronutrients or lipids, which might be patentable and offer differentiated value.
• Cost-Effective Manufacturing: Companies with efficient, high-volume manufacturing capabilities can achieve cost advantages, enabling them to compete effectively on price and capture market share, particularly in price-sensitive markets.
• Partnerships and Acquisitions: Strategic partnerships or acquisitions of smaller manufacturers or distributors could expand market reach and product portfolios.
• Focus on Quality and Reliability: In a market where price can be a significant factor, consistent high quality and reliable supply can become key differentiators, fostering customer loyalty among healthcare providers.

Key Takeaways

AMINOSYN 8.5% (PH6) operates within a stable but competitive segment of the parenteral nutrition market. Its financial performance is intrinsically linked to healthcare system expenditures and demographic trends such as population aging and the rise of chronic diseases. While the absence of strong composition of matter patents allows for generic competition, opportunities remain for manufacturers through efficient production, potential formulation enhancements, and expansion into emerging markets. Regulatory compliance remains a critical barrier to entry and a significant operational cost.

FAQs

1. Are there any new patents being filed for AMINOSYN 8.5% formulations? Patents are more likely to be filed for novel formulations, such as those with improved stability, bioavailability, or tailored compositions for specific patient needs, rather than for the standard AMINOSYN 8.5% composition itself, as its core intellectual property has expired.

2. How does the cost of AMINOSYN 8.5% compare to other parenteral nutrition components? The cost of AMINOSYN 8.5% is generally competitive within the parenteral nutrition market. Its price is often benchmarked against similar amino acid solutions from other manufacturers, and it represents one component of a complete parenteral nutrition regimen, which also includes carbohydrates, lipids, electrolytes, vitamins, and trace elements.

3. What is the typical shelf life of AMINOSYN 8.5% and how does it impact inventory management? The typical shelf life for AMINOSYN 8.5% varies by manufacturer and packaging, but it is generally between 18 to 24 months when stored under recommended conditions. This shelf life requires careful inventory management to avoid stockouts or expired product disposal, impacting logistical and financial planning.

4. What are the main adverse effects associated with AMINOSYN 8.5%? Potential adverse effects are generally related to the administration of any intravenous solution and can include fluid overload, electrolyte imbalances, and infusion site reactions. Specific to amino acid solutions, rare effects like nausea, vomiting, or allergic reactions can occur. These are well-documented in product labeling and clinical guidelines.

5. Does AMINOSYN 8.5% require refrigeration? AMINOSYN 8.5% typically does not require refrigeration. It is generally stored at controlled room temperature, typically between 20°C to 25°C (68°F to 77°F), as specified by the manufacturer to maintain product stability and integrity.

Citations

[1] Grand View Research. (2023). Parenteral Nutrition Market Size, Share & Trends Analysis Report by Product Type (Amino Acids, Vitamins, Carbohydrates), by Formulation, by Indication, by End-use, and Segment Forecasts, 2023-2030. [2] MarketsandMarkets. (2023). Parenteral Nutrition Market - Global Forecast to 2028. [3] United Nations, Department of Economic and Social Affairs, Population Division. (2022). World Population Prospects 2022. [4] Dulai, P. S., Singh, S., Probert, C. S., & Ghosh, S. (2017). Natural history of Crohn's disease and ulcerative colitis. World Journal of Gastroenterology, 23(37), 6596-6607. [5] Mordor Intelligence. (2023). Parenteral Nutrition Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028).